| 【Company Research】iQIYI (IQ US) - Membership and ad businesses remain under pressure; eye on short-drama development |
| 【Company Research】Dmall Inc (2586 HK) - End-to-end retail digitalization enabler |
| 【Sector Research】Capital Goods - Export volume growth across all machines in Dec |
| 【Company Research】Baidu (BIDU US) - Solid cloud revenue growth a bright spot in the stage of business adjustment |
| 【Company Research】Q-Tech (1478 HK) - Beneficiary of China smartphone subsidies; Raise TP to HK$6.79 |
| 【Company Research】BeiGene (ONC US) - Inflection point arrives: operating breakeven in 2025E |
| 【Sector Research】Technology - 4Q24 global smartphone shipments ahead; Xiaomi/Vivo outperformed Apple/Samsung |
| 【公司研究】巨子生物 (2367 HK) - 线上2024年线上增速靓丽，上调业绩指引 |
| 【Company Research】Xtep (1368 HK) - A beat in 4Q24 with a constructive outlook |
| 【Company Research】Kelun-Biotech (6990 HK) - Long-acting TSLP mAb out-licensed via NewCo model |
公司地址：香港中环花园道三号冠君大厦45-46楼
电话：（852）3900-0888 传真：（852）3761-8788
招银国际版权所有 Copyright © 2019-2026 CMB International Capital Corporation Limited. All rights reserved.
